Timing and clinical characteristics of topiramate-induced psychosis in a patient with epilepsy and tuberous sclerosis

Augusto Pasini, Mariabernarda Pitzianti, Antonia Baratta, Romina Moavero, Paolo Curatolo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Several lines of scientific evidence showed that topiramate may induce psychotic symptoms when used as monotherapy. It has been postulated that this topiramate effect may be caused by the inhibition of frontal and prefrontal areas induced by topiramate. The clinical history of the patient described shows that topiramate may also induce psychosis when used in polytherapy. A 34-year-old man, with epilepsy associated to tuberous sclerosis complex and without a previous history of mental disorders, presented an acute onset of florid psychotic symptoms, including visual and auditory hallucinations, derealization, and depersonalization. These symptoms appeared 1 month after the introduction of topiramate, added to levetiracetam and carbamazepine, when topiramate reached the dose of 200 mg daily. Once topiramate was discontinued, the psychotic symptoms disappeared, with no recurrence in a 4-month follow-up. Psychotic symptoms were associated with topiramate administration. We hypothesized that psychotic symptoms appeared a month after the topiramate introduction because of the slow topiramate titration and protective effect of carbamazepine.

Original languageEnglish
Pages (from-to)38-39
Number of pages2
JournalClinical Neuropharmacology
Volume37
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Tuberous Sclerosis
Psychotic Disorders
Epilepsy
Depersonalization
etiracetam
Hallucinations
Carbamazepine
topiramate
Mental Disorders
History
Recurrence

Keywords

  • epilepsy and tuberous sclerosis
  • topiramate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

Timing and clinical characteristics of topiramate-induced psychosis in a patient with epilepsy and tuberous sclerosis. / Pasini, Augusto; Pitzianti, Mariabernarda; Baratta, Antonia; Moavero, Romina; Curatolo, Paolo.

In: Clinical Neuropharmacology, Vol. 37, No. 1, 01.2014, p. 38-39.

Research output: Contribution to journalArticle

Pasini, Augusto ; Pitzianti, Mariabernarda ; Baratta, Antonia ; Moavero, Romina ; Curatolo, Paolo. / Timing and clinical characteristics of topiramate-induced psychosis in a patient with epilepsy and tuberous sclerosis. In: Clinical Neuropharmacology. 2014 ; Vol. 37, No. 1. pp. 38-39.
@article{bb50d156ae484a54ad74cc4aec6e1452,
title = "Timing and clinical characteristics of topiramate-induced psychosis in a patient with epilepsy and tuberous sclerosis",
abstract = "Several lines of scientific evidence showed that topiramate may induce psychotic symptoms when used as monotherapy. It has been postulated that this topiramate effect may be caused by the inhibition of frontal and prefrontal areas induced by topiramate. The clinical history of the patient described shows that topiramate may also induce psychosis when used in polytherapy. A 34-year-old man, with epilepsy associated to tuberous sclerosis complex and without a previous history of mental disorders, presented an acute onset of florid psychotic symptoms, including visual and auditory hallucinations, derealization, and depersonalization. These symptoms appeared 1 month after the introduction of topiramate, added to levetiracetam and carbamazepine, when topiramate reached the dose of 200 mg daily. Once topiramate was discontinued, the psychotic symptoms disappeared, with no recurrence in a 4-month follow-up. Psychotic symptoms were associated with topiramate administration. We hypothesized that psychotic symptoms appeared a month after the topiramate introduction because of the slow topiramate titration and protective effect of carbamazepine.",
keywords = "epilepsy and tuberous sclerosis, topiramate",
author = "Augusto Pasini and Mariabernarda Pitzianti and Antonia Baratta and Romina Moavero and Paolo Curatolo",
year = "2014",
month = "1",
doi = "10.1097/WNF.0000000000000014",
language = "English",
volume = "37",
pages = "38--39",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Timing and clinical characteristics of topiramate-induced psychosis in a patient with epilepsy and tuberous sclerosis

AU - Pasini, Augusto

AU - Pitzianti, Mariabernarda

AU - Baratta, Antonia

AU - Moavero, Romina

AU - Curatolo, Paolo

PY - 2014/1

Y1 - 2014/1

N2 - Several lines of scientific evidence showed that topiramate may induce psychotic symptoms when used as monotherapy. It has been postulated that this topiramate effect may be caused by the inhibition of frontal and prefrontal areas induced by topiramate. The clinical history of the patient described shows that topiramate may also induce psychosis when used in polytherapy. A 34-year-old man, with epilepsy associated to tuberous sclerosis complex and without a previous history of mental disorders, presented an acute onset of florid psychotic symptoms, including visual and auditory hallucinations, derealization, and depersonalization. These symptoms appeared 1 month after the introduction of topiramate, added to levetiracetam and carbamazepine, when topiramate reached the dose of 200 mg daily. Once topiramate was discontinued, the psychotic symptoms disappeared, with no recurrence in a 4-month follow-up. Psychotic symptoms were associated with topiramate administration. We hypothesized that psychotic symptoms appeared a month after the topiramate introduction because of the slow topiramate titration and protective effect of carbamazepine.

AB - Several lines of scientific evidence showed that topiramate may induce psychotic symptoms when used as monotherapy. It has been postulated that this topiramate effect may be caused by the inhibition of frontal and prefrontal areas induced by topiramate. The clinical history of the patient described shows that topiramate may also induce psychosis when used in polytherapy. A 34-year-old man, with epilepsy associated to tuberous sclerosis complex and without a previous history of mental disorders, presented an acute onset of florid psychotic symptoms, including visual and auditory hallucinations, derealization, and depersonalization. These symptoms appeared 1 month after the introduction of topiramate, added to levetiracetam and carbamazepine, when topiramate reached the dose of 200 mg daily. Once topiramate was discontinued, the psychotic symptoms disappeared, with no recurrence in a 4-month follow-up. Psychotic symptoms were associated with topiramate administration. We hypothesized that psychotic symptoms appeared a month after the topiramate introduction because of the slow topiramate titration and protective effect of carbamazepine.

KW - epilepsy and tuberous sclerosis

KW - topiramate

UR - http://www.scopus.com/inward/record.url?scp=84895076119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895076119&partnerID=8YFLogxK

U2 - 10.1097/WNF.0000000000000014

DO - 10.1097/WNF.0000000000000014

M3 - Article

VL - 37

SP - 38

EP - 39

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -